secwatch.observer — SEC 8-K summary
======================================

Issuer:     Avalo Therapeutics, Inc. (AVTX)
CIK:        0001534120
Form:       8-K
Filed at:   2025-11-06T23:59:59+00:00
Accession:  0001534120-25-000017
Event type: earnings
Sentiment:  neutral
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Avalo Therapeutics Q3 net loss $30.6M; completes Phase 2 LOTUS enrollment for AVTX-009
--------------------------------------------------------------------------------

- Completed enrollment in Phase 2 LOTUS trial (~250 adults) for AVTX-009 in hidradenitis suppurativa; topline data expected mid-2026.
- Cash and short-term investments $111.6M as of Sept 30, 2025; expected to fund operations into 2028.
- Net loss $30.6M in Q3 2025 vs net income $23.0M in Q3 2024; basic diluted EPS -$2.19.
- R&D expenses $13.6M (up $4.1M YoY) driven by LOTUS trial; G&A $5.6M (up $1.3M).
- Appointed Kevin Lind to Board; expanded leadership with new Chief Business Officer and SVP HR.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1534120/000153412025000017/0001534120-25-000017-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1534120/000153412025000017/avtx-20251106.htm
  HTML page:      https://secwatch.observer/filing/0001534120-25-000017

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer